401 related articles for article (PubMed ID: 11261530)
1. Orlistat--a novel weight loss therapy.
Lucas KH; Kaplan-Machlis B
Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
3. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
Leung WY; Thomas GN; Chan JC; Tomlinson B
Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
[TBL] [Abstract][Full Text] [Related]
4. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
Finer N; James WP; Kopelman PG; Lean ME; Williams G
Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
[TBL] [Abstract][Full Text] [Related]
5. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
[TBL] [Abstract][Full Text] [Related]
6. Orlistat in the treatment of obesity.
Ballinger A
Expert Opin Pharmacother; 2000 May; 1(4):841-7. PubMed ID: 11249520
[TBL] [Abstract][Full Text] [Related]
7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
8. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
[TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
[TBL] [Abstract][Full Text] [Related]
10. Long-term pharmacotherapy for obesity and overweight.
Padwal R; Li SK; Lau DC
Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
[TBL] [Abstract][Full Text] [Related]
11. Orlistat.
Wong NN; Cheng-Lai A
Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
[TBL] [Abstract][Full Text] [Related]
12. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
13. Orlistat: its current status as an anti-obesity drug.
Ballinger A; Peikin SR
Eur J Pharmacol; 2002 Apr; 440(2-3):109-17. PubMed ID: 12007529
[TBL] [Abstract][Full Text] [Related]
14. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
15. Orlistat, a new lipase inhibitor for the management of obesity.
Heck AM; Yanovski JA; Calis KA
Pharmacotherapy; 2000 Mar; 20(3):270-9. PubMed ID: 10730683
[TBL] [Abstract][Full Text] [Related]
16. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
Svendsen M; Helgeland M; Tonstad S
J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
[TBL] [Abstract][Full Text] [Related]
17. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
18. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.
Hill JO; Hauptman J; Anderson JW; Fujioka K; O'Neil PM; Smith DK; Zavoral JH; Aronne LJ
Am J Clin Nutr; 1999 Jun; 69(6):1108-16. PubMed ID: 10357727
[TBL] [Abstract][Full Text] [Related]
19. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men.
Pace DG; Blotner S; Guerciolini R
J Nutr; 2001 Jun; 131(6):1694-9. PubMed ID: 11385055
[TBL] [Abstract][Full Text] [Related]
20. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
Nelson RH; Miles JM
Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
